"The Role of LMWH’s in the Clinical Setting - Update 2002"

Flemings Prime Steakhouse and Wine Bar
(Hyatt Regency La Jolla at Aventine)

Map

To provide the participant with an overview of the current clinical and therapeutic options of Low Molecular Weight Heparin’s (LMWH) in the clinical setting and discuss appropriate risk stratification for usage in thromboembolism and acute coronary syndromes.

1. Understand the basic mechanisms of the thrombotic process and thrombogenesis.
2. Discuss the clinically pertinent differences between heparin and LMWH, and the differences among the LMWH class.

3. Briefly discuss the different prophylaxis strategies in patients at risk for venous thromboembolic disease.

4. Discuss current treatment strategies for the treatment of venous thromboembolism.

5. Discuss the use of antithrombotic therapy in patients with acute coronary syndromes. 

6. Discuss the current uses and role of LMWH’s in interventional procedures, such as coronary stent deployment.

Pre-Registration:

• FREE - members of SDCPhA & SDSHP
• $20.00 - non-member donation (refundable with membership application)

On Site Registration:  None

Limited Registration (please read)

In order to best serve those pharmacists with the most to gain from this talk, registration will be limited through May 7.  We ask that pharmacists who work in anticoagulation management, acute care, or who are involved in the prescribing, dispensing, or management of thromboembolic disorders in some manner (treatment and/or prevention) denote this in the position & message field below.  Pharmacists/technicians who do not meet the above criteria are asked to select "Waiting List"  within the position field whereby you will be notified of your registration during the second week in May.  Your cooperation is appreciated.